Infliximab is the Next Step
For a patient with sarcoidosis who has failed a year of steroids and methotrexate, the addition of infliximab is the recommended next-line therapy to improve and preserve lung function and quality of life. 1
Evidence-Based Rationale
The 2021 European Respiratory Society (ERS) clinical practice guidelines explicitly address this exact scenario. The guidelines state that for patients with symptomatic pulmonary sarcoidosis at higher risk of future mortality or permanent disability who have been treated with glucocorticoids or other immunosuppressive agents (including methotrexate) and have continued disease, infliximab should be added 1. This is a conditional recommendation based on low-quality evidence, but it represents the highest-level guideline available.
Treatment Algorithm Position
Your patient has progressed through the standard treatment escalation:
- First-line: Steroids (completed)
- Second-line: Methotrexate added to steroids (completed, failed after 1 year)
- Third-line: Infliximab (current recommendation)
The 2020 Delphi consensus from international sarcoidosis experts reinforces this approach, identifying infliximab as the preferred biologic agent for advanced disease that has failed steroids and methotrexate 2. The panel achieved consensus that infliximab is the first-choice biologic, supported by multiple clinical trials demonstrating efficacy across various sarcoidosis manifestations.
Dosing and Administration
Infliximab dosing: 3-5 mg/kg IV initially, repeated at 2 weeks, then every 4-6 weeks 1
Critical Safety Considerations
Before initiating infliximab, you must:
- Screen for latent tuberculosis (mandatory)
- Verify no history of severe congestive heart failure
- Rule out active infections, including deep fungal infections
- Check for prior malignancy or demyelinating neurologic disease
- Monitor for allergic reactions during infusions (can be life-threatening) 1
Alternative Options if Infliximab Fails or Is Contraindicated
While the guidelines prioritize infliximab, alternatives that did not reach full consensus but have supporting evidence include:
- Adalimumab (another anti-TNF agent, generally less toxic than infliximab) 2
- Rituximab (limited data, but some effectiveness reported) 2
- Repository corticotrophin injection (no consensus reached) 2
Expected Outcomes and Duration
The goal is to improve or preserve forced vital capacity (FVC) and quality of life 1. Continue biologics for 2-3 years if effective 2. Be aware that discontinuation after 6-12 months is associated with disease relapse in more than half of patients 1, so plan for prolonged therapy.
Steroid Management
While adding infliximab, taper corticosteroids to the lowest effective dose or discontinue if possible 2. This addresses the cumulative toxicity concern from your patient's year-long steroid exposure.
Common Pitfall to Avoid
Do not continue ineffective methotrexate indefinitely. The evidence shows that 80% of patients require reinstitution of systemic therapy after methotrexate withdrawal 1, and only 23% of methotrexate-treated patients showed improvement at 6 months compared to over half on infliximab 2. Your patient has already given methotrexate an adequate trial of one year—escalation is warranted.